Goal 3: Advance Translational Research

Novel Cell Apheresis Technologies to Treat Hematologic Diseases

Current FDA approved apheresis technology uses elutriation/centrifugation or filtration separation techniques to remove pathologic cellular and/or plasma elements. Currently these techniques are non-specific, limited by inefficient removal kinetics and often require considerable blood product exposure. Despite tremendous improvement in our understanding of the pathophysiology of a variety of disease, our ability to treat many of diseases using apheresis has not changed since the development of the modern cell separator in the 1980s. Development of novel apheresis technologies are needed to selectively remove unique cellular elements to improve current treatment modalities and/or provide novel treatment approaches in these patients.

Tags (Keywords associated with the idea)

Voting

118 net votes
139 up votes
21 down votes
Active
Idea No. 682